Michael A Carducci

Michael A Carducci

UNVERIFIED PROFILE

Are you Michael A Carducci?   Register this Author

Register author
Michael A Carducci

Michael A Carducci

Publications by authors named "Michael A Carducci"

Are you Michael A Carducci?   Register this Author

100Publications

4028Reads

28Profile Views

Genomic and clinical characterization of pulmonary-only metastatic prostate cancer: A unique molecular subtype.

Prostate 2019 Sep 7;79(13):1572-1579. Epub 2019 Aug 7.

Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pros.23881DOI Listing
September 2019

Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects.

Eur Urol 2019 Aug 4;76(2):170-176. Epub 2018 Oct 4.

Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins University, Baltimore, MD, USA; Brady Urological Institute, Johns Hopkins University, Baltimore, MD, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03022838183072
Publisher Site
http://dx.doi.org/10.1016/j.eururo.2018.09.040DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6447475PMC
August 2019

Improved identification of patients with oligometastatic clear cell renal cell carcinoma with PSMA-targeted F-DCFPyL PET/CT.

Ann Nucl Med 2019 Aug 30;33(8):617-623. Epub 2019 May 30.

The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, 600 North Wolfe Street, Park 213, Baltimore, MD, 21287, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12149-019-01371-8DOI Listing
August 2019

Investigational therapies targeting the androgen signaling axis and the androgen receptor and in prostate cancer - recent developments and future directions.

Expert Opin Investig Drugs 2018 10 31;27(10):811-822. Epub 2018 Aug 31.

a Sidney Kimmel Comprehensive Cancer Center , Johns Hopkins , Baltimore , MD , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13543784.2018.1513490DOI Listing
October 2018

Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series.

J Immunother Cancer 2018 10 11;6(1):104. Epub 2018 Oct 11.

Department of Medicine, Division of Rheumatology, Allergy and Immunology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

View Article

Download full-text PDF

Source
https://jitc.biomedcentral.com/articles/10.1186/s40425-018-0
Publisher Site
http://dx.doi.org/10.1186/s40425-018-0417-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180387PMC
October 2018

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.

J Clin Oncol 2018 04 31;36(11):1080-1087. Epub 2018 Jan 31.

Christos E. Kyriakopoulos, Glenn Liu, and David F. Jarrard, University of Wisconsin (UW) School of Medicine and Public Health and UW Carbone Cancer Center, Madison, WI; Yu-Hui Chen and Christopher J. Sweeney, Dana-Farber Cancer Institute; Yu-Hui Chen, Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group; Christopher J. Sweeney, Harvard Medical School, Boston, MA; Michael A. Carducci, Noah M. Hahn, and Mario Eisenberger, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD; Daniel H. Shevrin, NorthShore University HealthSystem, Evanston; Maha Hussain, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL; Robert Dreicer, University of Virginia Cancer Center, Charlottesville, VA; Manish Kohli, Mayo Clinic, Rochester, MN; Elizabeth R. Plimack, Fox Chase Cancer Center, Temple Health, Philadelphia, PA; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Joel Picus, Siteman Cancer Center, Washington University School of Medicine, St Louis, MO; Matthew M. Cooney, Seidman Cancer Center, University Hospitals Cleveland Medical Center; Jorge A. Garcia, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; and Robert S. DiPaola, University of Kentucky College of Medicine, Lexington, KY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.3657DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891129PMC
April 2018

Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer.

J Clin Oncol 2018 04 9;36(11):1088-1095. Epub 2018 Mar 9.

Alicia K. Morgans, Maha Hussain, and David Cella, Northwestern University Feinberg School of Medicine, Chicago, IL; Yu-Hui Chen and Christopher J. Sweeney, Dana Farber Cancer Institute, Boston, MA; David F. Jarrard, University of Wisconsin Hospital and Clinics, Madison, WI; Elizabeth R. Plimack, Fox Chase Cancer Center, Philadelphia, PA; Elizabeth R. Plimack and Benjamin A. Gartrell, Montefiore Medical Center, Bronx, NY; Michael A. Carducci, Johns Hopkins University, Baltimore, MD; Jorge A. Garcia, Cleveland Clinic, Cleveland, OH; Robert S. DiPaola, University of Kentucky College of Medicine, Lexington, KY; and Linda J. Patrick-Miller, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.3335DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891128PMC
April 2018

Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel.

J Clin Oncol 2018 02 20;36(4):376-382. Epub 2017 Dec 20.

Lauren C. Harshman and Christopher J. Sweeney, Dana-Farber Cancer Institute, Harvard Medical School; Yu-Hui Chen, Dana-Farber Cancer Institute, Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group, Boston, MA; Glenn Liu and David Jarrard, University of Wisconsin School of Medicine and Public Health and Carbone Cancer Center, Madison, WI; Michael A. Carducci, Noah Hahn, and Mario Eisenberger, Johns Hopkins University, Baltimore, MD; Robert Dreicer, University of Virginia Cancer Center, Charlottesville, VA; Jorge A. Garcia, Cleveland Clinic Taussig Cancer Institute; Matthew Cooney, University Hospitals Cleveland Medical Center, Seidman Cancer Center, Cleveland, OH; Maha Hussain, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago; Daniel Shevrin, NorthShore University Health System, Evanston, IL; Manish Kohli, Mayo Clinic, Rochester, MN; Elizabeth R. Plimack, Fox Chase Cancer Center, Temple Health, Philadelphia, PA; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Joel Picus, Siteman Cancer Center, Washington University School of Medicine, St Louis, MO; and Robert Dipaola, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.75.3921
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.75.3921DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805480PMC
February 2018

Second-Line Hormonal Therapy for Men With Chemotherapy-Naïve, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion.

J Clin Oncol 2017 Jun 25;35(17):1952-1964. Epub 2017 Apr 25.

Katherine S. Virgo, Emory University, Atlanta, GA; Ethan Basch, University of North Carolina, Chapel Hill, NC; D. Andrew Loblaw, Sunnybrook Health Sciences Centre, Toronto; Eric Winquist, London Health Sciences Centre, London, Ontario, Canada; Thomas K. Oliver and R. Bryan Rumble, American Society of Clinical Oncology, Alexandria, VA; Michael A. Carducci, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Luke Nordquist, Urology Cancer Center and GU Research Network, Omaha, NE; Mary-Ellen Taplin, Dana-Farber Cancer Institute, Boston, MA; and Eric A. Singer, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.72.8030DOI Listing
June 2017

Risk factors for metastatic prostate cancer: A sentinel event case series.

Prostate 2017 May 8;77(13):1366-1372. Epub 2017 Aug 8.

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/pros.23396
Publisher Site
http://dx.doi.org/10.1002/pros.23396DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5621513PMC
May 2017

Early use of chemotherapy in metastatic prostate cancer.

Cancer Treat Rev 2017 Apr 3;55:218-224. Epub 2016 Oct 3.

Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Baltimore, MD, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2016.09.017DOI Listing
April 2017

Reaffirming and Clarifying the American Society of Clinical Oncology's Policy Statement on the Critical Role of Phase I Trials in Cancer Research and Treatment.

J Clin Oncol 2017 01 28;35(2):139-140. Epub 2016 Nov 28.

Jeffrey S. Weber, New York University Langone Medical Center, New York, NY; Laura A. Levit, American Society of Clinical Oncology, Alexandria, VA; Peter C. Adamson, The Children's Hospital of Philadelphia, Philadelphia, PA; Suanna S. Bruinooge, American Society of Clinical Oncology, Alexandria, VA; Howard A. Burris III, Sarah Cannon Research Institute, Nashville, TN; Michael A. Carducci, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Adam P. Dicker, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA; Mithat Gönen, Memorial Sloan Kettering Cancer Center, New York, NY; Stephen M. Keefe, University of Pennsylvania, Philadelphia, PA; Michael A. Postow, Memorial Sloan Kettering Cancer Center, New York, NY; Michael A. Thompson, Aurora Health Care, Milwaukee, WI; David M. Waterhouse, Oncology Hematology Care, Cincinnati, OH; Susan L. Weiner, Children's Cause for Cancer Advocacy, Washington, DC; and Lynn M. Schuchter, University of Pennsylvania, Philadelphia, PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.4692DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5559890PMC
January 2017

Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN Study.

Prostate 2016 09 24;76(13):1218-26. Epub 2016 Jun 24.

Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pros.23209DOI Listing
September 2016

Improving an electronic system for measuring PROs in routine oncology practice.

J Cancer Surviv 2016 06 7;10(3):573-82. Epub 2015 Dec 7.

Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11764-015-0503-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4864116PMC
June 2016

A Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy With or Without Bevacizumab for Patients With Recurrent Prostate Cancer After Definitive Local Therapy.

J Clin Oncol 2016 06 4;34(16):1913-20. Epub 2016 Apr 4.

Rana R. McKay, Lillian Werner, Christopher J. Sweeney, Philip W. Kantoff, and Mary-Ellen Taplin, Dana-Farber Cancer Institute, Boston; Robert W. Ross, Bluebird Bio, Cambridge, MA; Amado J. Zurita and Hai T. Tran, MD Anderson Cancer Center, Houston, TX; Justine Y. Bruce, University of Wisconsin Carbone Cancer Center, Madison, WI; Michael A. Carducci, Johns Hopkins University; Arif Hussain, Greenebaum Cancer Center, Baltimore, MD; Mark N. Stein, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; Elisabeth I. Heath, Karmanos Cancer Institute, Detroit, MI; and Philip W. Kantoff and Susan F. Slovin, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.65.3154DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5321094PMC
June 2016

Relationship Between Quality of Comorbid Condition Care and Costs for Cancer Survivors.

J Oncol Pract 2016 06 10;12(6):e734-45. Epub 2016 May 10.

Johns Hopkins University Carey Business School; Johns Hopkins University School of Medicine; Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.2015.006098DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4957256PMC
June 2016

Challenges of conducting clinical trials of natural products to combat cancer.

Clin Adv Hematol Oncol 2016 Jun;14(6):447-55

Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, Maryland.

View Article

Download full-text PDF

Source
June 2016

Corrigendum to "Quantification of 5-azacytidine in plasma by electrospray tandem mass spectrometry coupled with high-performance liquid chromatography" [J. Chromatogr. B 813(1) (2004) 81-88].

J Chromatogr B Analyt Technol Biomed Life Sci 2016 May 25;1020:167. Epub 2016 Mar 25.

Division of Experimental Therapeutics, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting-Blaustein Cancer Research Building, 1650 Orleans Street, Room 1M87, Baltimore, MD 21231, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jchromb.2016.03.018DOI Listing
May 2016

A Retrospective Analysis of the Effect on Survival of Time from Diagnosis to Neoadjuvant Chemotherapy to Cystectomy for Muscle Invasive Bladder Cancer.

J Urol 2016 Apr 18;195(4 Pt 1):880-5. Epub 2015 Nov 18.

Department of Oncology, Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland; Department of Urology, Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2015.11.024DOI Listing
April 2016

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.

J Clin Oncol 2016 Apr 22;34(12):1402-18. Epub 2016 Feb 22.

Howard I. Scher, Michael J. Morris, Dana E. Rathkopf, and Susan F. Slovin, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College; David Nanus, NewYork Presbyterian Weill Cornell Medical Center; Lawrence W. Schwartz, NewYork Presbyterian Columbia University Medical Center, New York, NY; Walter M. Stadler, University of Chicago Medicine, Chicago, IL; Celestina Higano and Peter S. Nelson, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA; Ethan Basch, University of North Carolina at Chapel Hill, Chapel Hill, NC; Emmanual S. Antonarakis and Michael A. Carducci, Johns Hopkins University School of Medicine, Baltimore, MD; Tomasz M. Beer, Oregon Health and Science University, Portland, OR; Paul G. Corn and Christopher Logothetis, MD Anderson Cancer Center, Houston, TX; Robert Dreicer, University of Virginia School of Medicine, Charlottesville, VA; Daniel J. George, Susan Halabi, and Andrew J. Armstrong, Duke University and Duke Cancer Institute, Durham, NC; Elisabeth I. Heath, Wayne State University Karmanos Cancer Institute, Detroit; and Maha Hussain, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Wm. Kevin Kelly, Sidney Kimmel School of Medicine at Thomas Jefferson University, Philadelphia, PA; Glenn Liu and George Wilding, University of Wisconsin Carbone Cancer Center, Madison, WI; Mark N. Stein, The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ; Charles S. Ryan and Eric J. Small, University of California Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Oliver Sartor, Tulane School of Medicine, New Orleans, LA; Matthew Raymond Smith, Massachusetts General Hospital Cancer Center and Harvard Medical School; Mary-Ellen Taplin and Philip W. Kantoff, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, Franc

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.64.2702DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872347PMC
April 2016

New Treatment Options for Patients With Metastatic Prostate Cancer: What Is The Optimal Sequence?

Clin Genitourin Cancer 2015 Aug 21;13(4):271-279. Epub 2015 Jan 21.

Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2015.01.008DOI Listing
August 2015

American Society of Clinical Oncology policy statement update: the critical role of phase I trials in cancer research and treatment.

J Clin Oncol 2015 Jan 15;33(3):278-84. Epub 2014 Dec 15.

Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa, FL; Laura A. Levit and Suanna Bruinooge, American Society of Clinical Oncology, Alexandria, VA; Peter C. Adamson, Children's Hospital of Philadelphia; Adam P. Dicker, Jefferson Medical College, Thomas Jefferson University; Stephen M. Keefe and Lynn M. Schuchter, University of Pennsylvania, Philadelphia, PA; Howard A. Burris IIII, Sarah Cannon Research Institute, Nashville, TN; Michael A. Carducci, Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, MD; Mithat Gönen and Michael A. Postow, Memorial Sloan-Kettering Cancer Center, New York, NY; Michael A. Thompson, Aurora Health Care, Milwaukee, WI; David M. Waterhouse, Oncology Hematology Care, Cincinnati, OH; and Susan L. Weiner, Children's Cause for Cancer Advocacy, Washington, DC.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/33/3/278.full.pdf
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.58.2635
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.58.2635DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4516884PMC
January 2015

Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC).

Urol Oncol 2014 Nov 16;32(8):1308-16. Epub 2014 Sep 16.

Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY; Department of Medicine, Weill Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2014.08.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341998PMC
November 2014

Bone-targeting agents in prostate cancer.

Cancer Metastasis Rev 2014 Sep;33(2-3):619-28

Prostate Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, CRB1-1 M45, Baltimore, MD, 21231-1000, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10555-013-9480-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4087085PMC
September 2014

When using patient-reported outcomes in clinical practice, the measure matters: a randomized controlled trial.

J Oncol Pract 2014 Sep 1;10(5):e299-306. Epub 2014 Jul 1.

Johns Hopkins School of Medicine; Johns Hopkins Bloomberg School of Public Health; and Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.2014.001413DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161731PMC
September 2014

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.

N Engl J Med 2014 Sep 3;371(11):1028-38. Epub 2014 Sep 3.

From the Departments of Oncology (E.S.A., H.W., B.L., J.T.I., R.N., C.J.P., S.R.D., M.A.C., M.A.E.), Pathology (H.L.F., T.L.L., Q.Z., A.M.D.M.), and Urology (C.L., M.N., J.C.R., Yan Chen, W.B.I., J.L.), Johns Hopkins University School of Medicine, Baltimore; and Greehey Children's Cancer Research Institute (T.A.M., Yidong Chen) and the Department of Epidemiology and Biostatistics (Yidong Chen), University of Texas Health Science Center at San Antonio, San Antonio.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1315815DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4201502PMC
September 2014

Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer.

J Clin Oncol 2014 Apr 10;32(11):1136-42. Epub 2014 Mar 10.

Amir Goldkorn, David I. Quinn, and Tong Xu, University of Southern California Keck School of Medicine and Norris Comprehensive Cancer Center, Los Angeles; Przemyslaw Twardowski, City of Hope, Duarte; Philip C. Mack and Primo Lara Jr, University of California, Davis, Sacramento, CA; Benjamin Ely and Catherine M. Tangen, Southwest Oncology Group Statistical Center; Celestia S. Higano, Puget Sound Oncology Consortium, Seattle Cancer Care Alliance, and University of Washington, Seattle, WA; Louis M. Fink, Nevada Cancer Institute; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada and US Oncology Research, Las Vegas, NV; Peter J. Van Veldhuizen, University of Kansas Cancer Center, Westwood, KS; Neeraj Agarwal, University of Utah Huntsman Cancer Institute, Salt Lake City, UT; Michael A. Carducci, Johns Hopkins Kimmel Cancer Center and Eastern Cooperative Oncology Group, Baltimore, MD; J. Paul Monk III, Ohio State University and Cancer and Leukemia Group B, Columbus, OH; Ram H. Datar and Richard J. Cote, University of Miami Miller School of Medicine, Miami, FL; Mark Garzotto, Portland Veterans Affairs Medical Center, Portland, OR; Maha Hussain, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; and Ian Murchie Thompson Jr, University of Texas Health Science Center at San Antonio, San Antonio, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.51.7417DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3970171PMC
April 2014

Active smoking may negatively affect response rate, progression-free survival, and overall survival of patients with metastatic renal cell carcinoma treated with sunitinib.

Oncologist 2014 Jan 5;19(1):51-60. Epub 2013 Dec 5.

Genitourinary Oncology Service, Institute of Oncology, Meir Medical Center and the Sackler School of Medicine, Tel Aviv University, Kfar-Saba, Israel; Department of Oncology, Rambam Medical Center, Haifa, Israel; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA; Roswell Park Cancer Institute, Buffalo, New York, USA; Department of Oncology, Wolfson Medical Center, Holon, Israel; Department of Oncology, Asaf Harofe Medical Center, Zerifin, Israel; Department of Oncology, Sheba Medical Center, Tel Hashomer, Israel; Department of Oncology, Soroka University Medical Center, Beer-sheva, Israel.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2012-0335DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3903056PMC
January 2014

Using the EORTC-QLQ-C30 in clinical practice for patient management: identifying scores requiring a clinician's attention.

Qual Life Res 2013 Dec 27;22(10):2685-91. Epub 2013 Mar 27.

Division of General Internal Medicine, Johns Hopkins School of Medicine, 624 N. Broadway, Room 657, Baltimore, MD, 21205, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11136-013-0387-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3843980PMC
December 2013

Management of patients with biochemical recurrence after local therapy for prostate cancer.

Hematol Oncol Clin North Am 2013 Dec 18;27(6):1205-19, viii. Epub 2013 Sep 18.

Prostate Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, CRB1-1M59, Baltimore, MD 21287, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2013.08.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3818691PMC
December 2013

Dysregulation of the mammalian target of rapamycin pathway in chromophobe renal cell carcinomas.

Hum Pathol 2013 Oct 15;44(10):2323-30. Epub 2013 Aug 15.

Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA; Office of Scientific Research, Norte University, Asunción, Paraguay.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.humpath.2013.05.014DOI Listing
October 2013

Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors.

Epigenetics 2013 Sep 19;8(9):907-20. Epub 2013 Jul 19.

Department of Gynecology; Catharina Hospital Eindhoven; Eindhoven, The Netherlands; Prostate Cancer Program; Sidney Kimmel Comprehensive Cancer Center; Johns Hopkins University School of Medicine; Baltimore, MD USA; These authors contributed equally to this work.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/epi.25574DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3883768PMC
September 2013

Prevalence of pain and analgesic use in men with metastatic prostate cancer using a patient-reported outcome measure.

J Oncol Pract 2013 Sep 25;9(5):223-9. Epub 2013 Jun 25.

Memorial Sloan-Kettering Cancer Center, New York; Weill Cornell Medical College, New York, NY; Knight Cancer Institute, Oregon Health & Science University, Portland, OR; Duke University Medical Center, Durham; Cancer Outcomes Research Program, University of North Carolina, Chapel Hill, NC; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore; US Food and Drug Administration, Silver Spring, MD; and University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.2013.000876DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3994234PMC
September 2013

Screening assay for blood vessel maturation inhibitors.

Biochem Biophys Res Commun 2013 Aug 25;438(2):364-9. Epub 2013 Jul 25.

Department of Oncology, Johns Hopkins University, Baltimore, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbrc.2013.07.077DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4086510PMC
August 2013

From bevacizumab to tasquinimod: angiogenesis as a therapeutic target in prostate cancer.

Cancer J 2013 Jan-Feb;19(1):99-106

Prostate Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD 21287, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0b013e31827e0b86DOI Listing
July 2013

A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer.

Cancer Chemother Pharmacol 2013 Apr 13;71(4):883-92. Epub 2013 Jan 13.

Prostate Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, CRB1-1M45, Baltimore, MD 21231-1000, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-013-2079-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3609871PMC
April 2013

Management of bone metastases in refractory prostate cancer--role of denosumab.

Clin Interv Aging 2012 17;7:363-72. Epub 2012 Sep 17.

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, Baltimore, MD 21287, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CIA.S27930DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3459574PMC
February 2013

Removing barriers to participation in clinical trials, a conceptual framework and retrospective chart review study.

Trials 2012 Dec 10;13:237. Epub 2012 Dec 10.

Department of Environmental Health Sciences, Johns Hopkins Bloomberg School of Public Health, 615 North Wolfe Street, Baltimore, MD 21205, USA.

View Article

Download full-text PDF

Source
http://trialsjournal.biomedcentral.com/articles/10.1186/1745
Publisher Site
http://dx.doi.org/10.1186/1745-6215-13-237DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551829PMC
December 2012